 |
|
|
| Nov. 2000 |
|
Established M's Science Corporation, and licensed rights to SA4503 (Cutamesine) from Santen Pharmaceuticals Co., Ltd. |
 |
| Apr. 2001 |
|
Started joint research program with Nagoya University on cancer treatment using a herpes simplex virus (HF10). |
|
| Apr. 2001 |
|
Received the Research Business Award on New Technology from Small & Medium Enterprises and Regional Innovation, JAPAN. |
|
| Jul. 2001 |
|
Relocated headquarters to Minatojima-Minamimachi, Chuo-ku Kobe (Port Island). |
|
| Oct. 2002 |
|
Started Phase I clinical study with SA4503 (Cutamesine) in The Netherlands. |
|
| Jul. 2003 |
|
Certified for Creative Technology Research & Development Business by the Bureau of Economy, Trade and Industry. |
|
| Feb. 2004 |
|
Completed Phase Ia clinical study of SA4503 (Cutamesine) in The Netherlands. |
|
| Jul. 2004 |
|
Licensed certain rights of SA4503 (Cutamesine) to USA-based AGY Therapeutics Inc. |
|
| Dec. 2005 |
|
Completed human PET study of SA4503 (Cutamesine) in The Netherlands. |
|
| Mar. 2006 |
|
Acquired AGY Therapeutics' Neuroregeneration Program in its entirety, including all intellectual property and SA4503 analogues. M's has exclusive rights to the wholemolecule of SA4503. |
|
| Sep. 2006 |
|
Completed Phase 1b clinical study of SA4503 (Cutamesine) in The Netherlands. |
|
Aug. 2007 |
|
Phase 2a trial in Major Depression with SA4503 approved in Europe. |
|
Nov. 2007 |
|
Phase 2a trial in Stroke with SA4503 approved in Europe. |
|
Mar. 2008 |
|
Concluded option agreement for SA4503 with Eisai (priority review and negotiation right). |
|
Sep. 2008 |
|
Completed Phase 2a trial in Major Depression with SA4503 in Europe. |
|
Nov. 2008 |
|
Phase 1 trial in head and neck cancer with HF10 approved in the US. |
|
Aug. 2009 |
|
Completed Phase 2a trial in Stroke with SA4503 in Europe |
 |
 Remove to Top |
|
